← back to search

Francesco Raspagliesi

University of Milan · IT
Area of research
Obstetrics and Gynecology · Reproductive Medicine
Research interest
Research interests include Endometrial and Cervical Cancer Treatments, Ovarian cancer diagnosis and treatment, Cervical Cancer and HPV Research, and Uterine Myomas and Treatments.
h-index
69
citations
21,977
works
741
NIH funding
primary concept
Medicine
email

Recent publications

Comparison of ultrasound with computed tomography and whole-body diffusion-weighted MRI in prediction of surgical outcome using ESMO-ESGO criteria in patients with tubo-ovarian carcinoma: prospective ISAAC study.
2026cited by 0position: contributordoi
The future of gynecologic oncologic surgery: a narrative review of current surgical trials.
2026cited by 0position: contributordoi
Sentinel lymph node biopsy in vulvar cancer: current evidence, limitations, and future perspectives
Journal of Gynecologic Oncology 2026cited by 0position: contributordoi
Incorporating immune checkpoint inhibitors in epithelial ovarian cancer
Gynecologic Oncology 2025cited by 37position: middledoi
TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7).
Journal of Clinical Oncology 2025cited by 36position: middledoi
Malignant germ cells tumor of the ovary
Journal of Gynecologic Oncology 2025cited by 10position: middledoi
Risk factors for anastomotic leakage and its impact on survival outcomes in radical multivisceral surgery for advanced ovarian cancer: an AGO-OVAR.OP3/LION exploratory analysis
International Journal of Surgery 2025cited by 8position: middledoi
Malignant germ cells tumor of the ovary.
2025cited by 7position: contributordoi
Assessing the Reliability of Hysteroscopic Sampling Methods for Diagnosing Atypical Endometrial Hyperplasia
Cancers 2025cited by 0position: middledoi
Reliability of hysteroscopic sampling methods in diagnosing atypical endometrial hyperplasia: a matched cohort study
European Journal of Obstetrics & Gynecology and Reproductive Biology 2025cited by 0position: middledoi
Long-term survival analysis of a randomized phase II study of front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer (QPT-ORE-002).
Journal of Clinical Oncology 2025cited by 0position: middledoi
A STUDY OF NIRAPARIB IN COMBINATION WITH ABEMACICLIB FOR LATE LINE TREATMENT OF OVARIAN CANCER: A SINGLE CENTER, OPEN LABEL, SINGLE ARM, PHASE IB/II TRIAL (NICHOL TRIAL NCT06594679)
International Journal of Gynecological Cancer 2025cited by 0position: lastdoi
Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer
Annals of Oncology 2024cited by 120position: middledoi
Sentinel node mapping in high-intermediate and high-risk endometrial cancer: Analysis of 5-year oncologic outcomes
European Journal of Surgical Oncology 2024cited by 47position: middledoi
Targeting BRAF pathway in low-grade serous ovarian cancer.
2024cited by 44position: contributordoi
Sentinel node mapping in endometrial cancer.
2024cited by 36position: contributordoi
Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer
Leukemia 2024cited by 28position: middledoi
Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix
Proceedings of the National Academy of Sciences 2024cited by 15position: middledoi
Role of V-Y flap reconstruction in vulvar cancer patients: multicenter retrospective study
International Journal of Gynecological Cancer 2024cited by 6position: middledoi
Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group
Gynecologic Oncology 2024cited by 5position: middledoi
Correction: Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer
Leukemia 2024cited by 3position: middledoi
Ovarian Cancer Retrospective European (O'CaRE) study: first-line outcomes by number of risk factors for progression.
2024cited by 1position: contributordoi
1060 The role of VY flap reconstruction in vulvar cancer patients: a multicenter retrospective study
International Journal of Gynecological Cancer 2024cited by 0position: middledoi
733 Real world data of niraparib in platinum sensitive relapsed ovarian cancer: a multicenter experience of the MITO group
International Journal of Gynecological Cancer 2024cited by 0position: middledoi
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
New England Journal of Medicine 2023cited by 767position: middledoi
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer
Journal of Clinical Oncology 2023cited by 70position: middledoi
Outcomes of High-Grade Cervical Dysplasia with Positive Margins and HPV Persistence after Cervical Conization
Vaccines 2023cited by 68position: middledoi
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer
International Journal of Gynecological Cancer 2023cited by 48position: middledoi
Tisotumab vedotin in recurrent or metastatic cervical cancer
Current Problems in Cancer 2023cited by 32position: middledoi
Gestational choriocarcinoma
International Journal of Gynecological Cancer 2023cited by 30position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Giorgio Bogani · Clinica Universidad de Navarra31 papers (2019–2026)Fabio Martinelli · Humanitas University19 papers (2019–2021)Ignace Vergote · KU Leuven16 papers (2014–2024)Domenica Lorusso · Pontifícia Universidade Católica de São Paulo16 papers (2014–2025)Giorgio Bogani · Fondazione IRCCS Istituto Nazionale dei Tumori15 papers (2016–2025)Umberto Leone Roberti Maggiore · University of Parma14 papers (2019–2026) · 13 papers (2020–2026)Roberto Angioli · Università Campus Bio-Medico12 papers (2017–2025)Sandro Pignata · Iter11 papers (2018–2024)Jalid Sehouli · SLK-Kliniken Heilbronn10 papers (2017–2025)Giovanni Scambia · PromoFirenze9 papers (2017–2025)Antonino Ditto · National Cancer Institute9 papers (2019–2026) · 8 papers (2017–2024)Vanda Salutari · Woman's Hospital7 papers (2017–2025)Francesco Plotti · Università Campus Bio-Medico7 papers (2017–2025) · 7 papers (2017–2023)Ana Oaknin · Universitair Ziekenhuis Leuven7 papers (2014–2023)Isabelle Ray‐Coquard · Université Claude Bernard Lyon 17 papers (2014–2024)Valentina Chiappa · Tumori Foundation7 papers (2019–2026)Mauro Signorelli · Humanitas University7 papers (2019–2021)